glp 1 drugs oral GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is Oral GLP-1: A Needle-Free Solution

Teo C F, Wollaston-Hayden E E Wellsl

Nankivell VA, Sandeman L, Stretton L, Vidanapathirana AK, Rajora MA, Chen J

Ozempic as an add-on to basal insulin and Ozempic 1 mg vs 2 mg SUSTAIN 5: add-on basal insulin 1,10 In patients with type 2 diabetes on basal insulin metformin Secondary endpoint: mean change in body weight from baseline to Week 30 Mean baseline: 202 lb SUSTAIN FORTE: Ozempic 1 mg vs 2 mg 1,4,8 In patients with type 2 diabetes on metformin sulfonylurea Secondary endpoint: mean change in body weight from baseline to Week 40 Mean baseline: 219 lb Results based on sensitivity analyses of retrieved dropout population

Feel energized and supportednaturally.

When you look at the overall cost of treating obesity with these medications, the numbers are staggering